Evidence map›Paper›PMID 27526964›Full record

ArticleProstate cancer and prostatic diseases2016

Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005-2013: a population-based analysis.

K Lahdensuo, A Rannikko, V-J Anttila, A Erickson, A Pätäri-Sampo, M Rautio, H Santti, E Tarkka, M Vaara, K Huotari

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Rectal E. coli above ciprofloxacin ECOFF associate with infectious complications following prostate biopsy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018
    Trial
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

K LahdensuoDepartment of Urology, Meilahti Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
A RannikkoDepartment of Urology, Meilahti Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
V-J AnttilaDepartment of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
A EricksonInstitute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
A Pätäri-SampoDivision of Clinical Microbiology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
M RautioDivision of Clinical Microbiology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
H SanttiDepartment of Urology, Meilahti Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
E TarkkaDivision of Clinical Microbiology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
M VaaraDivision of Clinical Microbiology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
K HuotariDepartment of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
University of Helsinki · FIInstitute for Molecular Medicine Finland · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe most severe manifestations of prostate biopsy complications are bacteremic infections. These complications are increasing alarmingly.

methodsA retrospective cohort study of 17 183 transrectal prostate biopsies performed at the Helsinki and Uusimaa hospital district in southern Finland during 2005-2013. Biopsies were linked to a database of positive blood cultures, yielding 111 bacteremic cases, and yearly bacteremia rates were determined. By multiple regression analysis, demographic risk factors of the whole biopsy cohort for developing bacteremia or fluoroquinolone (FQ)-resistant bacteremia were studied. Clinical risk factors for bacteremia caused by an FQ-resistant organism and for serious bacteremic outcomes were studied by univariate and multivariate analyzes.

resultsThe average bacteremia rate was 0.7% (111 of 17 183 biopsies) and an increase was observed from 0.5% in 2005 (95% confidence interval (CI): 0.3-0.9) to 1.2% in 2012 (95% CI 0.8-1.8); 53.2% were caused by an FQ-resistant organism. In univariate regression analysis, previous biopsy sessions and increasing calendar year of biopsy associated with the risk of developing bacteremia (odds ratio (OR) 1.232, 95% CI: 1.020-1.488, P=0.030 and OR 1.164, 95% CI: 1.079-1.255, P<0.001, respectively), but only increasing calendar year of biopsy remained statistically significant (OR 1.155, 95% CI: 1.070-1.247, P<0.001) in multivariate analysis. Foreign travel within 3 months was associated with FQ resistance in multivariate analysis (OR 7.158, 95% CI: 1.042 to infinite, P=0.045). The study failed to show any significant clinical risk factors for serious bacteremic outcomes (requiring intensive care, developing deep infection foci or death).

conclusionsThe postbiopsy bacteremia rate doubled during the study period and half of the cases were caused by FQ-resistant organisms. Recent foreign travel increased the risk for FQ resistance. Future research efforts should be aimed at better identifying risk factors, targeted prophylaxis and reducing the need for biopsies.

Indexed as

AgedAnti-Bacterial AgentsBacteremiaBiopsyFinlandFluoroquinolonesHumansMaleProstateProstatic NeoplasmsRectumRetrospective StudiesRisk FactorsAnti-Bacterial AgentsFluoroquinolones

Identifiers

PMID27526964
OpenAlexW2511207713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.